{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\nO⁶‐Methylguanine‐DNA methyltransferase (MGMT) is a critical DNA repair enzyme that directly removes alkyl adducts from the O⁶ position of guanine, thereby protecting cells from the mutagenic and cytotoxic effects of alkylating agents. Structural studies reveal that MGMT functions by irreversibly accepting the alkyl group on an active‐site cysteine, and detailed mapping of its CpG island has identified specific regions whose methylation governs transcriptional silencing. In various cancers—including gliomas, colorectal and lung cancers—epigenetic modifications such as promoter hypermethylation have been shown to inactivate MGMT expression, thereby influencing both tumor development (e.g., through a field defect in colorectal mucosa) and clinical response to chemotherapy. This foundational evidence is bolstered by investigations of MGMT polymorphisms and their association with DNA damage biomarkers, as well as studies using small tissue samples that reliably capture its methylation status."}, {"type": "fg", "children": [{"type": "fg_fs", "start_ref": "1", "end_ref": "12"}]}, {"type": "t", "text": "\n"}]}, {"type": "t", "text": "\n\n"}, {"type": "p", "children": [{"type": "t", "text": "\nIn the clinical realm, MGMT promoter methylation has emerged as one of the most robust predictive biomarkers for response to alkylating chemotherapeutic agents—most notably temozolomide—in glioblastoma and other malignancies. Tumors harboring a methylated MGMT promoter tend to exhibit reduced enzyme expression, which in turn correlates with improved patient outcomes and prolonged survival. Quantitative methylation assays, real‐time PCR–based methods, and analyses of circulating tumor DNA have all contributed to refining MGMT assessment, while dynamic regulation (including inducible increases in MGMT transcript levels upon treatment) further illustrates its role in chemo‐resistance. In addition, studies in pediatric glioblastoma, recurrent disease, oligodendroglial tumors, and investigations combining promoter mapping with microRNA profiling underscore the complex regulation of MGMT and its significance in personalizing anticancer therapy."}, {"type": "fg", "children": [{"type": "fg_fs", "start_ref": "13", "end_ref": "24"}]}, {"type": "t", "text": "\n"}]}, {"type": "t", "text": "\n\n"}, {"type": "p", "children": [{"type": "t", "text": "\nBeyond its role as a predictive marker for temozolomide efficacy in glioblastoma, further investigations have expanded our understanding of MGMT’s clinical impact across diverse patient subsets and tumor types. In elderly patients and those with distinct imaging or molecular subtypes (e.g., defined by IDH1, 1p/19q, or TERT status), integrated models that include MGMT methylation offer refined prognostic stratification. Moreover, studies combining MGMT assessments with emerging therapeutic strategies—ranging from combination regimens with integrin inhibitors or oncolytic viruses to evaluations in aggressive pituitary tumors—highlight its central role in resistance mechanisms. Meta-analyses and comprehensive profiling efforts continue to validate the clinical utility of MGMT and stimulate ongoing discussions regarding the sometimes discordant relationship between promoter methylation and protein expression, ultimately underscoring the potential of MGMT modulation as a therapeutic target."}, {"type": "fg", "children": [{"type": "fg_fs", "start_ref": "25", "end_ref": "37"}]}, {"type": "t", "text": "\n"}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "Geoffrey P Margison, Andrew C Povey, Bernd Kaina, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Variability and regulation of O6-alkylguanine-DNA alkyltransferase."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Carcinogenesis (2003)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1093/carcin/bgg005"}], "href": "https://doi.org/10.1093/carcin/bgg005"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "12727789"}], "href": "https://pubmed.ncbi.nlm.nih.gov/12727789"}]}, {"type": "r", "ref": 2, "children": [{"type": "t", "text": "Tetsuji Nakagawachi, Hidenobu Soejima, Takeshi Urano, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Oncogene (2003)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/sj.onc.1207183"}], "href": "https://doi.org/10.1038/sj.onc.1207183"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "14647440"}], "href": "https://pubmed.ncbi.nlm.nih.gov/14647440"}]}, {"type": "r", "ref": 3, "children": [{"type": "t", "text": "Monika E Hegi, Annie-Claire Diserens, Sophie Godard, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Clin Cancer Res (2004)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1158/1078-0432.ccr-03-0384"}], "href": "https://doi.org/10.1158/1078-0432.ccr-03-0384"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "15041700"}], "href": "https://pubmed.ncbi.nlm.nih.gov/15041700"}]}, {"type": "r", "ref": 4, "children": [{"type": "t", "text": "Douglas S Daniels, Tammy T Woo, Kieu X Luu, et al. "}, {"type": "b", "children": [{"type": "t", "text": "DNA binding and nucleotide flipping by the human DNA repair protein AGT."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Nat Struct Mol Biol (2004)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/nsmb791"}], "href": "https://doi.org/10.1038/nsmb791"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "15221026"}], "href": "https://pubmed.ncbi.nlm.nih.gov/15221026"}]}, {"type": "r", "ref": 5, "children": [{"type": "t", "text": "Lanlan Shen, Yutaka Kondo, Gary L Rosner, et al. "}, {"type": "b", "children": [{"type": "t", "text": "MGMT promoter methylation and field defect in sporadic colorectal cancer."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Natl Cancer Inst (2005)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1093/jnci/dji275"}], "href": "https://doi.org/10.1093/jnci/dji275"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "16174854"}], "href": "https://pubmed.ncbi.nlm.nih.gov/16174854"}]}, {"type": "r", "ref": 6, "children": [{"type": "t", "text": "Shanbeh Zienolddiny, Daniele Campa, Helge Lind, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Polymorphisms of DNA repair genes and risk of non-small cell lung cancer."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Carcinogenesis (2006)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1093/carcin/bgi232"}], "href": "https://doi.org/10.1093/carcin/bgi232"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "16195237"}], "href": "https://pubmed.ncbi.nlm.nih.gov/16195237"}]}, {"type": "r", "ref": 7, "children": [{"type": "t", "text": "Sibille Everhard, Gentian Kaloshi, Emmanuelle Crinière, et al. "}, {"type": "b", "children": [{"type": "t", "text": "MGMT methylation: a marker of response to temozolomide in low-grade gliomas."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Ann Neurol (2006)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1002/ana.21044"}], "href": "https://doi.org/10.1002/ana.21044"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "17192931"}], "href": "https://pubmed.ncbi.nlm.nih.gov/17192931"}]}, {"type": "r", "ref": 8, "children": [{"type": "t", "text": "Eva M Grasbon-Frodl, Friedrich Wilhelm Kreth, Michael Ruiter, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Int J Cancer (2007)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1002/ijc.23020"}], "href": "https://doi.org/10.1002/ijc.23020"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "17691113"}], "href": "https://pubmed.ncbi.nlm.nih.gov/17691113"}]}, {"type": "r", "ref": 9, "children": [{"type": "t", "text": "Marta M Alonso, Candelaria Gomez-Manzano, B Nebiyou Bekele, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Cancer Res (2007)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1158/0008-5472.CAN-07-5312"}], "href": "https://doi.org/10.1158/0008-5472.CAN-07-5312"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "18089777"}], "href": "https://pubmed.ncbi.nlm.nih.gov/18089777"}]}, {"type": "r", "ref": 10, "children": [{"type": "t", "text": "Qinghua Feng, Stephen E Hawes, Joshua E Stern, et al. "}, {"type": "b", "children": [{"type": "t", "text": "DNA methylation in tumor and matched normal tissues from non-small cell lung cancer patients."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Cancer Epidemiol Biomarkers Prev (2008)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1158/1055-9965.EPI-07-2518"}], "href": "https://doi.org/10.1158/1055-9965.EPI-07-2518"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "18349282"}], "href": "https://pubmed.ncbi.nlm.nih.gov/18349282"}]}, {"type": "r", "ref": 11, "children": [{"type": "t", "text": "Matthias Preusser, Robert Charles Janzer, Jörg Felsberg, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Brain Pathol (2008)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1111/j.1750-3639.2008.00153.x"}], "href": "https://doi.org/10.1111/j.1750-3639.2008.00153.x"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "18400046"}], "href": "https://pubmed.ncbi.nlm.nih.gov/18400046"}]}, {"type": "r", "ref": 12, "children": [{"type": "t", "text": "Michael S Braun, Susan D Richman, Philip Quirke, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Clin Oncol (2008)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1200/JCO.2007.15.5580"}], "href": "https://doi.org/10.1200/JCO.2007.15.5580"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "18509181"}], "href": "https://pubmed.ncbi.nlm.nih.gov/18509181"}]}, {"type": "r", "ref": 13, "children": [{"type": "t", "text": "Katsuhiko Nosho, Takako Kawasaki, Mutsuko Ohnishi, et al. "}, {"type": "b", "children": [{"type": "t", "text": "PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Neoplasia (2008)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1593/neo.08336"}], "href": "https://doi.org/10.1593/neo.08336"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "18516290"}], "href": "https://pubmed.ncbi.nlm.nih.gov/18516290"}]}, {"type": "r", "ref": 14, "children": [{"type": "t", "text": "Ilse Vlassenbroeck, Stéphane Califice, Annie-Claire Diserens, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Mol Diagn (2008)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.2353/jmoldx.2008.070169"}], "href": "https://doi.org/10.2353/jmoldx.2008.070169"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "18556773"}], "href": "https://pubmed.ncbi.nlm.nih.gov/18556773"}]}, {"type": "r", "ref": 15, "children": [{"type": "t", "text": "Gaspar J Kitange, Brett L Carlson, Mark A Schroeder, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Neuro Oncol (2009)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1215/15228517-2008-090"}], "href": "https://doi.org/10.1215/15228517-2008-090"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "18952979"}], "href": "https://pubmed.ncbi.nlm.nih.gov/18952979"}]}, {"type": "r", "ref": 16, "children": [{"type": "t", "text": "Jörg Felsberg, Marion Rapp, Simon Loeser, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Clin Cancer Res (2009)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1158/1078-0432.CCR-08-2801"}], "href": "https://doi.org/10.1158/1078-0432.CCR-08-2801"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "19861461"}], "href": "https://pubmed.ncbi.nlm.nih.gov/19861461"}]}, {"type": "r", "ref": 17, "children": [{"type": "t", "text": "Martin J van den Bent, Hendrikus J Dubbink, Marc Sanson, et al. "}, {"type": "b", "children": [{"type": "t", "text": "MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Clin Oncol (2009)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1200/JCO.2009.24.1034"}], "href": "https://doi.org/10.1200/JCO.2009.24.1034"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "19901104"}], "href": "https://pubmed.ncbi.nlm.nih.gov/19901104"}]}, {"type": "r", "ref": 18, "children": [{"type": "t", "text": "Andreana L Rivera, Christopher E Pelloski, Mark R Gilbert, et al. "}, {"type": "b", "children": [{"type": "t", "text": "MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Neuro Oncol (2010)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1093/neuonc/nop020"}], "href": "https://doi.org/10.1093/neuonc/nop020"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "20150378"}], "href": "https://pubmed.ncbi.nlm.nih.gov/20150378"}]}, {"type": "r", "ref": 19, "children": [{"type": "t", "text": "Iris Lavon, Miri Refael, Bracha Zelikovitch, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Neuro Oncol (2010)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1093/neuonc/nop041"}], "href": "https://doi.org/10.1093/neuonc/nop041"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "20150384"}], "href": "https://pubmed.ncbi.nlm.nih.gov/20150384"}]}, {"type": "r", "ref": 20, "children": [{"type": "t", "text": "Francesca Pistollato, Sara Abbadi, Elena Rampazzo, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Stem Cells (2010)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1002/stem.415"}], "href": "https://doi.org/10.1002/stem.415"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "20309962"}], "href": "https://pubmed.ncbi.nlm.nih.gov/20309962"}]}, {"type": "r", "ref": 21, "children": [{"type": "t", "text": "Nathalie Gaspar, Lynley Marshall, Lara Perryman, et al. "}, {"type": "b", "children": [{"type": "t", "text": "MGMT-independent temozolomide resistance in pediatric glioblastoma cells associated with a PI3-kinase-mediated HOX/stem cell gene signature."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Cancer Res (2010)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1158/0008-5472.CAN-10-1250"}], "href": "https://doi.org/10.1158/0008-5472.CAN-10-1250"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "20935218"}], "href": "https://pubmed.ncbi.nlm.nih.gov/20935218"}]}, {"type": "r", "ref": 22, "children": [{"type": "t", "text": "Deborah S Malley, Rifat A Hamoudi, Sylvia Kocialkowski, et al. "}, {"type": "b", "children": [{"type": "t", "text": "A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Acta Neuropathol (2011)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1007/s00401-011-0803-5"}], "href": "https://doi.org/10.1007/s00401-011-0803-5"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "21287394"}], "href": "https://pubmed.ncbi.nlm.nih.gov/21287394"}]}, {"type": "r", "ref": 23, "children": [{"type": "t", "text": "Jörg Felsberg, Niklas Thon, Sabina Eigenbrod, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Int J Cancer (2011)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1002/ijc.26083"}], "href": "https://doi.org/10.1002/ijc.26083"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "21425258"}], "href": "https://pubmed.ncbi.nlm.nih.gov/21425258"}]}, {"type": "r", "ref": 24, "children": [{"type": "t", "text": "Radek Lakomy, Jiri Sana, Simona Hankeova, et al. "}, {"type": "b", "children": [{"type": "t", "text": "MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Cancer Sci (2011)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1111/j.1349-7006.2011.02092.x"}], "href": "https://doi.org/10.1111/j.1349-7006.2011.02092.x"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "21895872"}], "href": "https://pubmed.ncbi.nlm.nih.gov/21895872"}]}, {"type": "r", "ref": 25, "children": [{"type": "t", "text": "Guido Reifenberger, Bettina Hentschel, Jörg Felsberg, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Predictive impact of MGMT promoter methylation in glioblastoma of the elderly."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Int J Cancer (2012)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1002/ijc.27385"}], "href": "https://doi.org/10.1002/ijc.27385"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "22139906"}], "href": "https://pubmed.ncbi.nlm.nih.gov/22139906"}]}, {"type": "r", "ref": 26, "children": [{"type": "t", "text": "J A Carrillo, A Lai, P L Nghiemphu, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "AJNR Am J Neuroradiol (2012)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.3174/ajnr.A2950"}], "href": "https://doi.org/10.3174/ajnr.A2950"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "22322613"}], "href": "https://pubmed.ncbi.nlm.nih.gov/22322613"}]}, {"type": "r", "ref": 27, "children": [{"type": "t", "text": "Gaspar J Kitange, Ann C Mladek, Brett L Carlson, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Clin Cancer Res (2012)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1158/1078-0432.CCR-12-0560"}], "href": "https://doi.org/10.1158/1078-0432.CCR-12-0560"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "22675172"}], "href": "https://pubmed.ncbi.nlm.nih.gov/22675172"}]}, {"type": "r", "ref": 28, "children": [{"type": "t", "text": "Pierre Bady, Davide Sciuscio, Annie-Claire Diserens, et al. "}, {"type": "b", "children": [{"type": "t", "text": "MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Acta Neuropathol (2012)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1007/s00401-012-1016-2"}], "href": "https://doi.org/10.1007/s00401-012-1016-2"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "22810491"}], "href": "https://pubmed.ncbi.nlm.nih.gov/22810491"}]}, {"type": "r", "ref": 29, "children": [{"type": "t", "text": "Wolfgang Wick, Christoph Meisner, Bettina Hentschel, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Neurology (2013)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1212/WNL.0b013e3182a95680"}], "href": "https://doi.org/10.1212/WNL.0b013e3182a95680"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "24068788"}], "href": "https://pubmed.ncbi.nlm.nih.gov/24068788"}]}, {"type": "r", "ref": 30, "children": [{"type": "t", "text": "Remco J Molenaar, Dagmar Verbaan, Simona Lamba, et al. "}, {"type": "b", "children": [{"type": "t", "text": "The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Neuro Oncol (2014)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1093/neuonc/nou005"}], "href": "https://doi.org/10.1093/neuonc/nou005"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "24510240"}], "href": "https://pubmed.ncbi.nlm.nih.gov/24510240"}]}, {"type": "r", "ref": 31, "children": [{"type": "t", "text": "Roger Stupp, Monika E Hegi, Thierry Gorlia, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Lancet Oncol (2014)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/S1470-2045(14)70379-1"}], "href": "https://doi.org/10.1016/S1470-2045(14"}, {"type": "t", "text": "70379-1) PMID: "}, {"type": "a", "children": [{"type": "t", "text": "25163906"}], "href": "https://pubmed.ncbi.nlm.nih.gov/25163906"}]}, {"type": "r", "ref": 32, "children": [{"type": "t", "text": "Daniel Bengtsson, Henrik Daa Schrøder, Marianne Andersen, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Clin Endocrinol Metab (2015)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1210/jc.2014-4350"}], "href": "https://doi.org/10.1210/jc.2014-4350"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "25646794"}], "href": "https://pubmed.ncbi.nlm.nih.gov/25646794"}]}, {"type": "r", "ref": 33, "children": [{"type": "t", "text": "Gloria Perazzoli, Jose Prados, Raul Ortiz, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "PLoS One (2015)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1371/journal.pone.0140131"}], "href": "https://doi.org/10.1371/journal.pone.0140131"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "26447477"}], "href": "https://pubmed.ncbi.nlm.nih.gov/26447477"}]}, {"type": "r", "ref": 34, "children": [{"type": "t", "text": "Hideyuki Arita, Kai Yamasaki, Yuko Matsushita, et al. "}, {"type": "b", "children": [{"type": "t", "text": "A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Acta Neuropathol Commun (2016)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1186/s40478-016-0351-2"}], "href": "https://doi.org/10.1186/s40478-016-0351-2"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "27503138"}], "href": "https://pubmed.ncbi.nlm.nih.gov/27503138"}]}, {"type": "r", "ref": 35, "children": [{"type": "t", "text": "Maryam Moradi Binabaj, Afsane Bahrami, Soodabeh ShahidSales, et al. "}, {"type": "b", "children": [{"type": "t", "text": "The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Cell Physiol (2018)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1002/jcp.25896"}], "href": "https://doi.org/10.1002/jcp.25896"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "28266716"}], "href": "https://pubmed.ncbi.nlm.nih.gov/28266716"}]}, {"type": "r", "ref": 36, "children": [{"type": "t", "text": "Erica H Bell, Peixin Zhang, Barbara J Fisher, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "JAMA Oncol (2018)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1001/jamaoncol.2018.1977"}], "href": "https://doi.org/10.1001/jamaoncol.2018.1977"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "29955793"}], "href": "https://pubmed.ncbi.nlm.nih.gov/29955793"}]}, {"type": "r", "ref": 37, "children": [{"type": "t", "text": "Madison Butler, Lorinc Pongor, Yu-Ting Su, et al. "}, {"type": "b", "children": [{"type": "t", "text": "MGMT Status as a Clinical Biomarker in Glioblastoma."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Trends Cancer (2020)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1016/j.trecan.2020.02.010"}], "href": "https://doi.org/10.1016/j.trecan.2020.02.010"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "32348734"}], "href": "https://pubmed.ncbi.nlm.nih.gov/32348734"}]}]}]}